Abstract: A display device may include a substrate including a display area and a non-display area; and a plurality of pixels disposed in the display area, the plurality of pixels each including an emission area and a non-emission area. Each of the plurality of pixels may include at least one light emitting element in the emission area; a first pixel electrode and a second pixel electrode electrically connected to the at least one light emitting element; a bank including a first opening corresponding to the emission area; a color conversion layer disposed in the emission area to correspond to the at least one light emitting element; a barrier layer disposed on the bank and the color conversion layer; and a low refractive layer disposed on the barrier layer. The barrier layer may include silicon oxide (SiOx) having cured polysilazane.

Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.

Abstract: A display device according to one or more embodiments of the disclosure includes a pixel circuit layer including a base layer and circuit elements on the base layer; and a display layer on the pixel circuit layer. The display layer includes a first electrode on the pixel circuit layer; an insulating layer on the first electrode; a second electrode on the insulating layer; a light emitting stacked structure on the second electrode and including a first insulating layer, a second insulating layer, and a light emitting layer between the first insulating layer and the second insulating layer; and a third electrode on the light emitting stacked structure. The light emitting layer includes a two-dimensional material, is separated from the second electrode by the first insulating layer, and is separated from the third electrode by the second insulating layer.

Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-CD19 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD19, as well as methods of making and using these anti-CD19 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.

Abstract: The present invention relates to a pyrrolobenzodiazepine derivative compound, a conjugate of the same with a ligand, and the use of the same. The pyrrolobenzodiazepine derivative compound is more stable in plasma, is stable even in circulation, and exhibits excellent efficacy. In particular, the conjugate of the pyrrolobenzodiazepine derivative compound with a ligand has a great advantage in that it is possible to target and specifically treat proliferative disease such as cancer, maximize drug efficacy, and minimize the expression of side effects since the conjugate more stably reaches the target cell and effectively exerts drug efficacy while toxicity is greatly reduced as a linker technology that allows drugs to be easily released within cancer cells and maximize drug efficacy is incorporated.

Abstract: A color conversion panel includes: a substrate; a plurality of banks disposed on the substrate, where the banks partition a first light emitting region, a second light emitting region, and a third light emitting region; a first color conversion layer disposed in the first light emitting region, a second color conversion layer disposed in the second light emitting region, and a transmission layer disposed in the third light emitting region; and a first reflective layer disposed to overlap the first color conversion layer and the second color conversion layer, where the first reflective layer includes a first layer, a second layer, and a third layer, a refractive index of the second layer is greater than a refractive index of the third layer, and the refractive index of the third layer is greater than a refractive index of the first layer.

Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-CD19 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD19, as well as methods of making and using these anti-CD19 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.

Abstract: The present invention relates to a pyrrolobenzodiazepine dimer prodrug and a ligand-linker conjugate compound thereof, a composition containing these, and therapeutic use thereof particularly as an anticancer drug. The stability of the compounds themselves and the stability thereof in plasma are excellent and the compounds are advantageous in terms of manifestation of toxicity, and thus the compounds are industrially useful in that it is possible to target proliferative diseases such as cancer, to perform a specific treatment, to maximize the drug efficacy, and to minimize the occurrence of side effects.

Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

Abstract: A display device includes a substrate including a display area, and a non-display area, and dams disposed in the non-display area. Each of the dams surrounds the display area, the dams include a first dam adjacent to the display area, second dams surrounding the first dam, and third dams surrounding the second dams. The second dams are spaced apart from each other, the third dams are spaced apart from each other, and opposing ends of at least one of the second dams and the third dams has a curvature.

Abstract: The present disclosure relates to pyrrolobenzodiazepine dimer prodrugs and ligand-linker conjugates thereof. The present disclosure also relates to compositions and uses of said prodrugs and conjugates.

Abstract: A display device is provided. The display device comprises a transistor layer disposed on a substrate, a light emitting element layer disposed on the transistor layer, a wavelength conversion layer disposed on the light emitting element layer, and a first capping layer disposed on the wavelength conversion layer, wherein the first capping layer includes a base, and hollow particles mixed in the base. The base includes polysilazane, the polysilazane including siloxane.

Abstract: A display device and a method of manufacturing the display device are provided. The display device includes pixels and a bank including an opening overlapping each of the pixels in a plan view, light emitting elements disposed in the pixels, a color conversion layer disposed on the light emitting elements in the opening of the bank, and an optical layer disposed on the color conversion layer in the opening of the bank. The optical layer includes an organic layer surrounding voids of the optical layer.

Abstract: A display device includes a light emitting element disposed on a substrate. A color conversion layer is disposed on the light emitting element, the color conversion layer including color conversion particles that convert light of a first color emitted from the light emitting element into light of a second color. An insulating layer is disposed on the color conversion layer. The insulating layer includes a first inorganic layer overlapping the color conversion layer, a second inorganic layer disposed on the first inorganic layer, and a third inorganic layer disposed on the second inorganic layer. A second porosity of the second inorganic layer is greater than a first porosity of the first inorganic layer. A second porosity of the second inorganic layer is greater than a third porosity of the third inorganic layer.

Abstract: A display device may include: a substrate including a display area including a pixel area, and a non-display area including a pad area and located at at least one side of the display area; a pixel in the pixel area, the pixel including an emission area in which at least one light emitting element is located, and a non-emission area adjacent to the emission area; a pad in the pad area, the pad being electrically connected to the pixel; a first layer on the light emitting element at the pixel area; and a second layer in the pixel area and the pad area, the second layer including a pad opening formed exposing at least a portion of the pad. The first layer may include an organic layer including a hollow particle. The first layer may be spaced from the pad opening and covered with the second layer.

Abstract: The display device includes sub-pixels disposed in a display area, dummy pixels disposed in a non-display area, a first bank disposed at a boundary between the sub-pixels and including an opening, a second bank disposed at a boundary between the dummy pixels and including an opening, a color conversion layer disposed in the opening of the first bank, and an organic layer disposed in the opening of the second bank.

Abstract: A display device may include a substrate including a display area and a non-display area; and a plurality of pixels disposed in the display area, the plurality of pixels each including an emission area and a non-emission area. Each of the plurality of pixels may include at least one light emitting element in the emission area; a first pixel electrode and a second pixel electrode electrically connected to the at least one light emitting element; a bank including a first opening corresponding to the emission area; a color conversion layer disposed in the emission area to correspond to the at least one light emitting element; a barrier layer disposed on the bank and the color conversion layer; and a low refractive layer disposed on the barrier layer. The barrier layer may include silicon oxide (SiOx) having cured polysilazane.

Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting DLK1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically, uses for such ADCs in producing drugs for treatment and/or prevention of proliferative and/or angiogenetic diseases, for example, cancer. More particularly, the present invention relates to an antibody-drug conjugate comprising an antibody binding with DLK1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.